Press Release Source: Albany Molecular Research, Inc. On Monday October 3, 2011, 8:00 am EDT
ALBANY, N.Y.--(BUSINESS WIRE)-- AMRI (NASDAQ:AMRI - News) announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla. Nicholas Moore, Ph.D., director of development and pharmacology at AMRI, reported results from a second Phase I study showing cerebrospinal fluid (CSF) drug levels were achieved with a single 400 mg oral dose of ALB-127158(a). The finding is significant in that it indicates brain/CNS penetration and suggests the compound will reach the drug target receptor in the brain.
Dr. Moore also reiterated previously reported results from a placebo-controlled study which evaluated the safety, tolerability, and efficacy of ALB-127158(a). The study, comprising the single ascending dose (SAD) and 14-day multiple ascending dose (MAD) arms, included standard safety assessments, ECG monitoring, and PK measurements. ALB-127158(a) was well tolerated in both the SAD and the MAD. Reported events were mild and showed little dose relationship. One of the most common events reported in both the SAD and the MAD was loss of appetite. Reductions in “hunger,” “desire to eat,” and test meal consumption were observed. The study met both its primary and secondary objectives, demonstrating safety and tolerability.
Analysis of the CSF and other data suggested a higher than predicted dose would be required for chronic treatment. Therefore, AMRI has decided not to progress ALB-127158(a) further.
“Although we have decided not to progress ALB-127158(a) toward Phase II clinical studies, we have multiple follow-on compounds that we believe may show better potential for partnering and clinical development,” said Bruce Sargent, Ph.D., senior vice president of drug discovery.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM